TransMedics Group (NASDAQ:TMDX) Reaches New 1-Year Low – Here’s Why

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) hit a new 52-week low during trading on Thursday . The company traded as low as $60.40 and last traded at $60.88, with a volume of 1588704 shares traded. The stock had previously closed at $65.71.

Analyst Ratings Changes

TMDX has been the topic of a number of research reports. Oppenheimer restated an “outperform” rating and set a $125.00 price objective on shares of TransMedics Group in a research report on Tuesday, December 3rd. Robert W. Baird decreased their price target on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a research note on Wednesday, December 11th. JPMorgan Chase & Co. restated a “neutral” rating and issued a $75.00 price objective (down previously from $116.00) on shares of TransMedics Group in a research note on Tuesday. Canaccord Genuity Group decreased their target price on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating on the stock in a research report on Wednesday, November 20th. Finally, Needham & Company LLC restated a “hold” rating on shares of TransMedics Group in a research note on Wednesday, December 11th. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $122.70.

TransMedics Group Stock Performance

The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. The stock has a market capitalization of $2.04 billion, a price-to-earnings ratio of 64.77 and a beta of 2.06. The stock’s 50-day simple moving average is $91.40 and its 200 day simple moving average is $129.80.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.17). The business had revenue of $108.76 million during the quarter, compared to analyst estimates of $115.00 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The firm’s revenue was up 63.7% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.12) earnings per share. Analysts expect that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

Insider Transactions at TransMedics Group

In other news, insider Tamer I. Khayal sold 2,958 shares of the stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $148.24, for a total transaction of $438,493.92. Following the sale, the insider now directly owns 20,843 shares of the company’s stock, valued at $3,089,766.32. This represents a 12.43 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Waleed H. Hassanein sold 8,625 shares of the firm’s stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $132.71, for a total transaction of $1,144,623.75. Following the completion of the sale, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at approximately $8,180,642.53. This represents a 12.27 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 19,417 shares of company stock worth $2,240,738. Insiders own 7.00% of the company’s stock.

Institutional Investors Weigh In On TransMedics Group

Institutional investors and hedge funds have recently made changes to their positions in the company. Amalgamated Bank increased its position in TransMedics Group by 6.7% in the second quarter. Amalgamated Bank now owns 1,114 shares of the company’s stock worth $168,000 after purchasing an additional 70 shares during the period. Harbour Capital Advisors LLC boosted its stake in shares of TransMedics Group by 1.7% in the 3rd quarter. Harbour Capital Advisors LLC now owns 4,841 shares of the company’s stock valued at $760,000 after purchasing an additional 81 shares during the last quarter. Signaturefd LLC grew its position in shares of TransMedics Group by 26.6% during the 2nd quarter. Signaturefd LLC now owns 443 shares of the company’s stock worth $67,000 after buying an additional 93 shares during the period. Arizona State Retirement System raised its stake in shares of TransMedics Group by 2.1% during the second quarter. Arizona State Retirement System now owns 9,158 shares of the company’s stock worth $1,379,000 after buying an additional 186 shares during the last quarter. Finally, Venturi Wealth Management LLC raised its stake in shares of TransMedics Group by 33.7% during the third quarter. Venturi Wealth Management LLC now owns 869 shares of the company’s stock worth $136,000 after buying an additional 219 shares during the last quarter. Institutional investors own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.